<DOC>
	<DOCNO>NCT02759419</DOCNO>
	<brief_summary>Provide riociguat therapy patient Pulmonary Arterial Hypertension ( PAH ) originate Bayer-sponsored trial 12935 PATENT-2 16719 RESPITE currently recently treat trial lack patient benefit , commercial availability reimbursement .</brief_summary>
	<brief_title>A Long-term Extension Study Riociguat Patients With Symptomatic Pulmonary Arterial Hypertension .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Patients diagnose Pulmonary Arterial Hypertension ( PAH ) participate participate Bayersponsored study 12935 16719 , complete main study phase still treat riociguat ( either still treatment respective study drug commercial mean Adempas ) , opinion investigator , expect continue overall positive benefit/risk continue treatment . Women men reproductive potential must agree use adequate contraception sexually active . This applies time period signing informed consent form 30 day last administration study drug . Ongoing serious adverse event ( SAE ) originate study assess related riociguat Pregnant woman breastfeed woman . Any contraindication Adempas treatment list SmPC ( Summary Product Characteristics ) Concomitant participation another clinical study study drug . Patients pulmonary Hypertension associate idiopathic Interstitial pneumonia ( PHIIP )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>